Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA244551
Max Phase: Preclinical
Molecular Formula: C15H13F3N2O4S
Molecular Weight: 374.34
Molecule Type: Small molecule
Associated Items:
ID: ALA244551
Max Phase: Preclinical
Molecular Formula: C15H13F3N2O4S
Molecular Weight: 374.34
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: C[C@@H](C(=O)Nc1ccccn1)c1ccc(OS(=O)(=O)C(F)(F)F)cc1
Standard InChI: InChI=1S/C15H13F3N2O4S/c1-10(14(21)20-13-4-2-3-9-19-13)11-5-7-12(8-6-11)24-25(22,23)15(16,17)18/h2-10H,1H3,(H,19,20,21)/t10-/m1/s1
Standard InChI Key: AMYIMGJGQIODLB-SNVBAGLBSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 374.34 | Molecular Weight (Monoisotopic): 374.0548 | AlogP: 3.05 | #Rotatable Bonds: 5 |
Polar Surface Area: 85.36 | Molecular Species: NEUTRAL | HBA: 5 | HBD: 1 |
#RO5 Violations: 0 | HBA (Lipinski): 6 | HBD (Lipinski): 1 | #RO5 Violations (Lipinski): 0 |
CX Acidic pKa: 11.97 | CX Basic pKa: 4.03 | CX LogP: 4.18 | CX LogD: 4.18 |
Aromatic Rings: 2 | Heavy Atoms: 25 | QED Weighted: 0.64 | Np Likeness Score: -1.20 |
1. Moriconi A, Cesta MC, Cervellera MN, Aramini A, Coniglio S, Colagioia S, Beccari AR, Bizzarri C, Cavicchia MR, Locati M, Galliera E, Di Benedetto P, Vigilante P, Bertini R, Allegretti M.. (2007) Design of noncompetitive interleukin-8 inhibitors acting on CXCR1 and CXCR2., 50 (17): [PMID:17665889] [10.1021/jm061469t] |
2. Moriconi A, Bigogno C, Bianchini G, Caligiuri A, Resconi A, Dondio MG, D'Anniballe G, Allegretti M.. (2011) Aryltriflates as a Neglected Moiety in Medicinal Chemistry: A Case Study from a Lead Optimization of CXCL8 Inhibitors., 2 (10): [PMID:24900265] [10.1021/ml2001533] |
Source(1):